Liang H, Liu Y, Guo J, Dou M, Zhang X, Hu L, Chen J. Progression in immunotherapy for advanced prostate cancer. Front Oncol. 2023;13:1126752.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, Gavin A, Flego M, Neamtiu L, Dimitrova N et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47.

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–90.

Article  PubMed  PubMed Central  Google Scholar 

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.

Article  PubMed  PubMed Central  Google Scholar 

Gentile F, La Civita E, Ventura BD, Ferro M, Bruzzese D, Crocetto F, Tennstedt P, Steuber T, Velotta R, Terracciano D. A neural Network Model combining [-2]proPSA, freePSA, total PSA, Cathepsin D, and Thrombospondin-1 showed increased accuracy in the identification of clinically significant prostate cancer. Cancers. 2023;15(5).

Ma J, Li L, Liao T, Gong W, Zhang C. Efficacy and safety of (225)Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-resistant prostate Cancer: a systematic review and Meta-analysis. Front Oncol. 2022;12:796657.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alam MR, Singh SB, Thapaliya S, Shrestha S, Deo S, Khanal K. A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging Theranostic agents in prostate Cancer. Cureus. 2022;14(9):e29369.

PubMed  PubMed Central  Google Scholar 

Huang EM, Ma N, Ma T, Zhou JY, Yang WS, Liu CX, Hou ZH, Chen S, Zong Z, Zeng B, et al. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma. World J Gastrointest Oncol. 2022;14(10):1981–2003.

Article  PubMed  PubMed Central  Google Scholar 

Aznaourova M, Schmerer N, Schmeck B, Schulte LN. Disease-causing mutations and rearrangements in long non-coding RNA Gene Loci. Front Genet. 2020;11:527484.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sánchez-Ares M, Cameselle-García S, Abdulkader-Nallib I, Rodríguez-Carnero G, Beiras-Sarasquete C, Puñal-Rodríguez JA, Cameselle-Teijeiro JM. Susceptibility genes and chromosomal regions Associated with non-syndromic familial non-medullary thyroid carcinoma: some pathogenetic and diagnostic Keys. Front Endocrinol. 2022;13:829103.

Article  Google Scholar 

Hong L, Wang H, Wang J, Wei S, Zhang F, Han J, Liu Y, Ma M, Liu C, Xu Y, et al. LncRNA PTCSC3 inhibits Tumor Growth and Cancer Cell Stemness in Gastric Cancer by interacting with lncRNA linc-pint. Cancer Manage Res. 2019;11:10393–9.

Article  CAS  Google Scholar 

Zhang H, Wang J, Xun W, Wang J, Song W, Wang X. Long non-coding RNA PTCSC3 inhibits human oral cancer cell proliferation by inducing apoptosis and autophagy. Archives Med Science: AMS. 2021;17(2):492–9.

Article  CAS  Google Scholar 

Tong R, Zhang J, Wang C, Li X, Yu T, Wang L. LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. Clin Exp Pharmacol Physiol. 2020;47(3):439–48.

Article  CAS  PubMed  Google Scholar 

Zeng L, Liao Q, Zeng X, Ye J, Yang X, Zhu S, Tang H, Liu G, Cui W, Ma S, et al. Noncoding RNAs and hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Bioengineered. 2022;13(2):2623–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B. Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine. 2020;99(7):e18993.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang CH, Cheng TY, Yeh WW, Luo YL, Campbell M, Kuo TC, Shen TW, Hong YC, Tsai CH, Peng YC, et al. REST-repressed lncRNA LINC01801 induces neuroendocrine differentiation in prostate cancer via transcriptional activation of autophagy. Am J cancer Res. 2023;13(9):3983–4002.

CAS  PubMed  PubMed Central  Google Scholar 

Tang Q, Li Z, Han W, Cheng S, Wang Y. High expression of lncRNA SNHG1 in prostate cancer patients and inhibition of SNHG1 suppresses cell proliferation and promotes apoptosis. Indian J Pathol Microbiol. 2020;63(4):575–80.

Article  PubMed  Google Scholar 

Xing P, Wang Y, Zhang L, Ma C, Lu J. Knockdown of lncRNA MIR4435–2HG and ST8SIA1 expression inhibits the proliferation, invasion and migration of prostate cancer cells in vitro and in vivo by blocking the activation of the FAK/AKT/β–catenin signaling pathway. Int J Mol Med. 2021;47(6).

Jiang B, Chen Y, Xia F, Li X. PTCSC3-mediated glycolysis suppresses thyroid cancer progression via interfering with PGK1 degradation. J Cell Mol Med. 2021;25(17):8454–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang N, Hou M, Zhan Y, Sheng X. LncRNA PTCSC3 inhibits triple-negative breast cancer cell proliferation by downregulating lncRNA H19. J Cell Biochem. 2019;120(9):15083–8.

Article  CAS  PubMed  Google Scholar 

Zhang G, Gao L, Zhang J, Wang R, Wei X. Long non–coding RNA PTCSC3 suppresses triple–negative breast cancer by downregulating long non–coding RNA MIR100HG. Oncol Lett. 2023;26(2):331.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao D, Cui X, Wang X. LncRNA PTCSC3 inhibits cell proliferation in laryngeal squamous cell carcinoma by down-regulating lncRNA HOTAIR. Biosci Rep. 2019;39(6).

Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z, et al. MiR-182-5p and miR-375-3p have higher performance than PSA in discriminating prostate cancer from benign prostate hyperplasia. Cancers. 2021;13(9).

Souza MF, Cólus IMS, Fonseca AS, Antunes VC, Kumar D, Cavalli LR. MiR-182-5p modulates prostate cancer aggressive phenotypes by targeting EMT associated pathways. Biomolecules. 2022;12(2).

Yao J, Xu C, Fang Z, Li Y, Liu H, Wang Y, Xu C, Sun Y. Androgen receptor regulated microRNA mir-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem Biophys Res Commun. 2016;474(1):213–9.

Article  CAS  PubMed  Google Scholar